Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Down 0.8 %

Shares of AKTX opened at $1.18 on Wednesday. The firm’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $2.60. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC grew its holdings in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. Institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.